EMA Recommends Extension of Indications for Pomalidomide
New indication concerns treatment of adult patients with multiple myeloma in combination with bortezomib and dexamethasone after at least one prior regimen including lenalidomide
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indication concerns treatment of adult patients with multiple myeloma in combination with bortezomib and dexamethasone after at least one prior regimen including lenalidomide
EMA published questions-and-answers document for patients, healthcare professionals and the general public
Insights from the patient-derived xenograft models of breast cancer in mice
Pertuzumab, with intravenous trastuzumab and chemotherapy, is recommended for the adjuvant treatment of HER2-positive early stage breast cancer in adults at high risk of recurrence
It is recommended in patients with ALK-positive advanced NSCLC who have already had crizotinib
EMA will assess available data in relation to existing screening methods to detect DPD deficiency
Approval is based on results from the IMpower133 study
It is recommended for use as an option for treatment of adults with diffuse large B-cell lymphoma after 2 or more systemic therapies
Tumour specific splicing presents a large new class of splicing associated potential neoantigens
Findings from GINECO case-control study
Approval is based on results from the IMpassion130 trial
They are recommended as an option for treatment of adults with unresectable or metastatic BRAF V600 mutation-positive melanoma
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.